Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiochem Inc.

Division of AngioChem Inc.
www.angiochem.com

Latest From Hutchison MediPharma Ltd.

Pipeline Watch: Phase III Zytiga, Cadazolid And Upadacitinib Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Big Pharma CEOs Descend On China: What’s The Likely Agenda?

In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.

China Policy & Regulation

Top Asia Execs To Watch: WuXi NextCode, Fosun Kite, Novartis Japan

The coming of spring has brought a flurry of senior executive moves at companies across Asia including WuXi, Fosun-Kite, Novartis, BGI and Chi-Med.

Appointments Asia Pacific

Pipeline Watch: Phase III Starts With Durvalumab, Atezolimumab And Eravacycline

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • AngioChem Inc.
  • Senior Management
  • Jean-Paul Castaigne, MD, Pres. & CEO
    Betty Lawrence, VP, Dev.
    Dejan Ristic, Acting Head, Fin.
    Catherine Gagnon, Dir., Corp. Dev.
    Jean E Lachowicz, PhD, CSO
  • Contact Info
  • Angiochem Inc.
    Phone: (514) 788-7800
    201 President-Kennedy Ave.
    Ste. PK-R220
    Montreal, H2X 3Y7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register